HCW Biologics (NASDAQ:HCWB – Get Free Report) and Inozyme Pharma (NASDAQ:INZY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Profitability
This table compares HCW Biologics and Inozyme Pharma’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
HCW Biologics | -978.03% | -385.90% | -126.44% |
Inozyme Pharma | N/A | -88.42% | -57.02% |
Earnings and Valuation
This table compares HCW Biologics and Inozyme Pharma”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
HCW Biologics | $3.92 million | 3.47 | -$24.99 million | ($1.04) | -0.35 |
Inozyme Pharma | N/A | N/A | -$71.17 million | ($1.56) | -2.56 |
Volatility & Risk
HCW Biologics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for HCW Biologics and Inozyme Pharma, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
HCW Biologics | 0 | 0 | 0 | 0 | 0.00 |
Inozyme Pharma | 0 | 0 | 7 | 0 | 3.00 |
Inozyme Pharma has a consensus price target of $15.71, suggesting a potential upside of 292.86%. Given Inozyme Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Inozyme Pharma is more favorable than HCW Biologics.
Institutional & Insider Ownership
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 49.9% of HCW Biologics shares are held by insiders. Comparatively, 11.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Inozyme Pharma beats HCW Biologics on 8 of the 13 factors compared between the two stocks.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
About Inozyme Pharma
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.